Zusammenfassung
Der Diabetes mellitus ist für Neurologen, die sich mit dem Schlaganfall beschäftigen, aus zweierlei Gesichtpunkten von klinischem Interesse. In der Akutphase eines Hirninfarktes ist eine optimierte Kontrolle des Blutzuckers prognostisch relevant, zweitens ist eine optimale Behandlung erhöhter Blutzuckerwerte langfristig als modifizierbarer Risikofaktor entscheidend. Aufgrund fehlender Evidenz wurde die intensivierte Blutzuckersenkung durch intravenöse Insulingabe als Standardverfahren auf der Stroke-Unit durch ein moderateres Behandlungsregime abgelöst. Aktuell wird bei geringer bis mäßiger Hyperglykämie über 200 mg / dl zunächst eine subkutane Insulingabe favorisiert, erst bei mehr als 6 erforderlichen Gaben wird eine intravenöse Insulindauerinfusion empfohlen. Obwohl epidemiologisch eine Korrelation zwischen Höhe des HbA1c und der Häufigkeit zerebraler Infarkte besteht und ausreichend Präparate zur effektiven Senkung des HbA1c vorliegen, führten die Ergebnisse der großen Interventionsstudien (ACCORD, ADVANCE, V-ADT) zu widersprüchlichen Empfehlungen zur Höhe der Blutzuckersenkung. Aus der Nachbeobachtung der UKPDS sowie der Steno-2-Studie liegen uns positive Daten für eine frühzeitig begonnene Behandlung vor. Dies hat zu einem Umdenken in der Diabetesbehandlung geführt. Statt der generellen Festlegung auf einen, für alle Diabetiker gültigen optimalen HbA1c-Wert, sind Behandlungsempfehlungen, die auch Erkrankungsdauer, Komorbiditäten und Nebenwirkungen der Antidiabetika berücksichtigen, von einer größeren Individualisierung geprägt. Neben der frühzeitig begonnenen Behandlung muss vor allem ein multimodaler Therapieansatz mit Berücksichtigung der Komplexizität eines möglichen metabolischen Syndroms erfolgen, wie Studien zur Effektivität einer Lebensstiländerung und Blutdrucksenkung bei Typ-2-Diabetes gezeigt haben.
Abstract
The diabetic metabolic state has two different implications for the neurologist engaged in stroke treatment. An ideal treatment of diabetes mellitus is of enormous concern due to its significance as a risk factor for emerging atherosclerotic diseases such as stroke, as well as in acute stroke, owing to its relevance for the clinical outcome. Intensified blood glucose lowering regimens using i. v. insulin are currently being replaced by a more liberal therapy on the Stroke Unit. Blood glucose levels beyond 200 mg% will be treated by fractionated s. c. insulin administration, only in the case of failure is i. v. continuous insulin to be used. In spite of available epidemiological data for the correlation between glycated haemoglobin and stroke prevalence, as well as the existence of numerous drugs effective in reducing HBA1c, many intervention studies (ACCORD, ADVANCE, V-ADT) have failed to show a close connection for reducing clinical endpoints. The data from STENO-2 and the UKPDS have led to the idea that in the long run the positive effects of antidiabetic strategies will be better revealed. The primarily disappointing data from the intervention studies challenged the diabetes treatment. It seems clear that there is no magic optimum of a target HBA1c which fits for all patients. Instead of this approach we will need an individualised therapy taking into account age, comorbidity, duration of diabetes and side effects of drugs. Besides the early start of an optimised diabetes therapy, the additional treatment of the metabolic syndrome is essential for the best care. This has best been shown by studies which have shown the positive effects of life-style modifications and blood pressure treatment in diabetic patients.
Schlüsselwörter
Schlaganfall - Diabetes mellitus - Hyperglykämie
Keywords
stroke - diabetes - hyperglycaemia
Literatur
-
1
Wild S, Roglic G, Green A. et al .
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care.
2004;
27
1047-1053
-
2
Seufert J.
Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2-Diabetes-mellitus. Cardiovascular outcome studies in type 2 diabetes therapy.
Arztebl.
2006;
103
A-934/B-791/C-765
-
3
Parvez H, Bisher K, Meguid N.
Obesity and Diabetes in the Developing World – A Growing Challenge.
NEJM.
2008;
356
213-215
-
4
Moss S E, Klein R, Klein B E.
Causespecific mortality in a population-based study of diabetes.
Am J Public Health.
1991;
81
1158-1162
-
5
Fox C S, Coady S, Sorlie P D. et al .
Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham. Heart Study.
Circulation.
2007;
115
1544-1550
-
6
Martin S, Schramm W, Schneider B. et al .
Epidemiology of Complications and Total Treatment Costs from Diagnosis of type 2 diabetes in Germany (ROSSO 4).
Exp Clin Endocrinol Diabetes.
2007;
115
1-7
-
7
Howard B V, Best L G, Galloway J M. et al .
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors.
Diabetes Care.
2006;
29
391-397
-
8
Thomas J, Johnson J, Simpson S. et al .
Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes.
Stroke.
2007;
38
1739-1743
-
9
Weir C J, Murray G D, Dyker A G. et al .
Is hyperglycemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow-up study.
BMJ.
1997;
314
1303-1309
-
10
Bruno A, Biller J, Adams Jr H P. et al .
Acute blood glucose level and outcome from ischemic stroke.
Neurology.
1999;
52
280-284
-
11
Cox N H, Lorains J W.
The prognostic value of blood glucose and glycosylated haemoglobin estimation in patients with stroke.
Postgrad Med J.
1986;
62
7-10
-
12
Murros K, Fogelholm R, Kettunen S. et al .
Serum cortisol and outcome of ischemic brain infarction.
J Neurol Sci.
1993;
116
12-17
-
13
Lin B, Ginsberg M D, Busto R.
Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alternations.
Avta Neuropathol.
1998;
96
610-620
-
14
Gisselsson L, Smith M L, Siejo B K.
Hyperglycemia and local brain ischemia.
J Cereb Blood Flow Metabol.
1999;
19
288-297
-
15
Hoxworth J M, Xu K, Zhou Y. et al .
Cerebral metabolic profile, selective neuron loss, and survival of acute and chronic hyperglycaemic rats following cardiac arrest and resuscitation.
Brain res.
1999;
821
467-479
-
16
Anderson R E, Tan W K, Martin H S. et al .
Effects of glucose and PaO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra.
Stroke.
1999;
30
160-170
-
17
Lee J M, Zipfel G J, Choi D W.
The changing landscape of ischemic brain injury mechanisms.
Nature.
1999;
399
A7-A14
-
18
Li P A, Shuaib A, Miyashita H. et al .
Hyperglycemia enhances extracellular glutamate accumulation in rats subjected to forebrain ischemia.
Stroke.
2000;
31
183-192
-
19
Siesjo B K, Zhao Q, Pahlmark K. et al .
Glutamate, calcium and free radicals as mediators of ischemic brain damage.
Ann Thorac Surg.
1995;
59
1316-1320
-
20
Kawai N, Keep R F, Betz A L.
Effects of hyperglycemia on cerebral blood flow and edema formation after carotid artery occlusion in Fischer 344 rats.
Acta Neurochir Suppl (Wien).
1997;
70
34-36
-
21
Dietrich W D, Alonso O, Busto R.
Moderate hyperglycemia worsens acute bloodbrain barrier injury after forebrain ischemia in rats.
Stroke.
1993;
24
111-116
-
22
Ribo M, Molina C, Montaner J. et al .
Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients.
Stroke.
2005;
36
1705-1709
-
23
Els T, Klisch J, Orszagh M. et al .
Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size.
Cerebrovasc Dis.
2002;
13
89-94
-
24
Bruno H A, Levine S R, Frankel M R. et al .
Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke.
Neurology.
2002;
59
67-71
-
25
Ronning O M, Guldvog B.
Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial.
Stroke.
1998;
29
8-62
-
26 Hess D, Langhorne P. Stroke Unit Trialists' Collaboration: Organized Inpatient (Stroke Unit) Care for Stroke (Cochrane-Review). In: The Cochrane Library, Issue 2. Chichester, UK; John Wiley & Sons, Ltd 2004
-
27
Van den Berghe G, Wouters P, Weekers F. et al .
Intensive Insulin Therapy in Critically Ill Patients.
N Engl J Med.
2001;
345
1359-1367
-
28
Van den Berghe G, Wilmer A, Hermans G. et al .
Intensive Insulin Therapy in the Medical ICU.
N Engl J Med.
2006;
354
449-461
-
29
Brunkhorst F, Engel C, Bloos F. et al, for the German Competence Network Sepsis (SepNet) .
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
N Engl J Med.
2008;
358
125-139
-
30
The NICE-SUGAR Study Investigators .
Intensive versus conventional glucose control in critically ill patients.
N Engl J Med.
2009;
360
1283-1297
-
31
Griesdale D E, de Souza R J, van Dam R M. et al .
Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data.
CMAJ.
2009;
180
821-827
-
32
Van den Berghe G, Mesotten D, Vanhorebeek I.
Commentary. Intensive insulin therapy in the intensive care unit.
CMAJ.
2009;
14
180
-
33
Gray C S, Hildreth A J, Sandercock P A. et al .
Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK).
Lancet Neurol.
2007;
6
397-406
-
34
Moss S E, Klein R, Klein B E. et al .
The association of glycemia and causespecific mortality in a diabetic population.
Arch Intern Med.
1994;
154
2473-2479
-
35
Selvin E, Marinopoulos S, Berkenblit G. et al .
Meta-analysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus.
Ann Intern Med.
2004;
141
421
-
36
Sung S, Song Y, Ebrahim S. et al .
Fasting blood glucose and the risk of stroke and myocardial infarction.
Circulation.
2009;
119
765-767
-
37
UK Prospective Diabetes Study (UKPDS) Group .
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33).
Lancet.
1998;
352
837-853
, Erratum, Lancet 1999; 354: 602
-
38
UK Prospective Diabetes Study (UKPDS) Group .
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
, Erratum, Lancet 1998; 352: 1558
-
39
Simpson S H. et al .
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
CMAJ.
2006;
174
169-174
-
40
Abraira C, Colwell J, Nuttall F. et al .
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial.
Arch Intern Med.
1997;
157
181-188
-
41
Ohkubo Y, Kishikawa H, Araki E. et al .
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract.
1995;
28
103-117
-
42
Stettler C, Allemann S, Jüni P. et al .
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials.
Am Heart J.
2006;
152
27-38
-
43
Meinert C L, Knatterud G L, Prout T E. et al .
A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.
Diabetes.
1970;
19 (Suppl.)
789-830
-
44
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group .
Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med.
2008;
358
2545-2559
-
45
The ADVANCE Collaborative Group .
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med.
2008;
358
2560-2572
-
46
William Duckworth for the VADT Investigators .
Glucose control and vascular complications in veterans with type 2 diabetes.
N Engl J Med.
2009;
360
129-139
-
47
Holman R, Paul S, Bethel A. et al .
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1565-1576
-
48
Gaede P, Lund-Andersen H, Parving H H. et al .
Effect of multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med.
2008;
358
580-591
-
49
The Diabetes Control and Complications Trial Research Group .
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med.
1993;
329
-
50
Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Research Group .
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.
N Engl J Med.
2003;
348
2294-2303
-
51
Nathan D M. et al .
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
NEJM.
2005;
353
2643-2653
-
52
Ray K K, Seshasai S R, Wijesuriya S. et al .
Effects of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials.
Lancet.
2009;
373
1765
-
53
Martin S, Kolb H, Schneider B. et al .
Myocardial infarction and stroke in early years after diagnosis of type 2 diabetes: risk factors and relation to self-monitoring of blood glucose.
Diabetes Technol Ther.
2009;
11
234-241
-
54
Nissen E S, Wolski K.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
N Engl J Med.
2007;
356
2457-2471
-
55
Gerstein H C, Yusuf S, Bosch J. et al .
The DREAM-Study: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
Lancet.
2006;
368
1096-1105
-
56
Singh S, Loke J, Furberg C.
Long-term risk of cardiovascular events with rosiglitazon.
JAMA.
2007;
298
1198-1195
-
57
Home P D, Pocock S J, Beck-Nielsen H. et al., RECORD Study Group .
Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes.
N Engl J Med.
2007;
375
28-38
-
58
Richter B, Bandeira-Echtler E, Bergerhoff K. et al .
Rosiglitazone for type 2 diabetes mellitus.
Cochrane Database Syst Rev.
2007;
3
-
59
Bolen S, Feldman L, Vassy J. et al .
Comparative effectiveness and safety of oral medications for type diabetes mellitus.
Ann Intern Med July 16.
2007;
-
60
Lipscombe L, Gomes T, Lévesque L.
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
JAMA.
2007;
298
2634-2643
-
61
Lincoff A M, Wolski K, Nicholls S J. et al .
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials.
JAMA.
2007;
298
1180-1188
-
62
Lago R M, Singh P P, Nesto R W.
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lancet.
2007;
370
1129-1136
-
63
Singh S, Loke Y K, Furberg C D.
Thiazolidinediones and heart failure: a teleo-analysis.
Diabetes Care.
2007;
30
2148-2153
-
64
Dormandy J A, Charbonnel B, Eckland D J. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial.
Lancet.
2005;
366
1279-1289
-
65
Bertoni A G, Blumenthal S, Philippides G. et al .
Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the american heart association.
Circulation.
2009;
119
3244-3262
, originally published online Jun 8, 2009; in the Young; Council on Cardiovascular Nursing; Council on Nutrition, Physical Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention
-
66
Li G, Zhang P, Wang J. et al .
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Quing Diabetes Prevention Study.
Lancet.
2008;
371
1783-1789
-
67
The Look AHEAD Research Group .
One year results from the Look AHEAD Research Group.
Diabetes Care.
2007;
30
1374-1383
-
68
Ogawa H, Nakayama M, Morimoto T. et al .
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
JAMA.
2008;
300
2180-2181
-
69
Steering Committee of the Physicians' Health Study Research Group .
Final report on the aspirin component of the ongoing Physicians' Health Study.
N Engl J Med.
1989;
321
129-135
-
70
Sacco M, Pellegrini F, Roncaglioni M C. PPP Collaborative Group .
Primary prevention of cardiovascular events with lowdose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Diabetes Care.
2003;
26
3264-3272
-
71
Hansson L, Zanchetti A, Carruthers S G. et al .
Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group.
Lancet.
1998;
351
1755-1762
-
72
Murphy A.
Women's Health Study: Low dose aspirin in primary prevention.
J Am Coll Cardiol.
2005;
46
CS7-CS8
-
73
Arterial Disease and Diabetes Study Group, Diabetes Registry Group .
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease Arterial Disease and Diabetes Study Group, Diabetes Registry Group.
BMJ.
2008;
337
1840
-
74
Heart Protection Study Collaborative Group .
Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Lancet.
2002;
360
7-22
-
75
Plehn J, Davis B, Sacks F M. et al, for the CARE Investigators .
Reduction of stroke incidence after myocardial infarction with pravastatin.
Circulation.
1999;
99
216-223
-
76
Scandinavian Simvastatin Survival Study Group .
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet.
1994;
344
1383-1389
-
77
Colhoun H, Betteridge D, Durrington P. et al .
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetic Med.
2007;
24
1313-1321
-
78
Knopp R, d'Emden M, Smilde J. et al .
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN).
Diabetes Care.
2006;
29
1478-1485
-
79
Wanner C, Krane V, März W. et al, the German Diabetes and Dialysis Study Investigators .
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med.
2005;
353
238-248
-
80
Cholesterol Treatment Trialists' Collaborators .
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet.
2008;
371
117
Dr. Nikolaus Schmidt
Dr. Horst Schmidt Klinik GmbH Wiesbaden, Klinik für Neurologie
Ludwig-Erhard-Str. 100
65199 Wiesbaden
Email: nikolaus.schmidt@hsk-wiesbaden.de
